Fuso Pharmaceutical Industries,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

The company reported a significant increase in operating and net income relative to revenue growth, supported by operating leverage from reductions in selling, general and administrative expenses. Revenue was ¥160.5B (+3.5% YoY), operating income was ¥9.7B (+63.0%), ordinary income was ¥9.1B (+40.9%), and net income was ¥6.4B (+39.0%). The gross margin was 26.2%, broadly in line with the previous year, while the improvement in the SG&A ratio (20.1%, approximately -2.4pt YoY) was the primary driver of earnings growth.

Factors Affecting Results

【Revenue】Revenue increased 3.5% YoY to ¥160.5B. Although segment information was not disclosed, progress against the full-year forecast (¥632.0B, YoY +1.4%) was 25.4%, a standard level.

【Profit and Loss】Operating income increased significantly by 63.0% YoY to ¥9.7B, and the operating margin improved by +2.2pt from 3.8% in the previous year to 6.1%. While the cost of sales ratio was broadly flat, SG&A expenses declined 3.5% to ¥32.2B, reducing the SG&A ratio to 20.1%, which was the primary driver of earnings growth. In non-operating items, interest expense increased from ¥0.7B to ¥1.0B, increasing the interest burden; however, ordinary income rose 40.9% to ¥9.1B, as the improvement at the operating level absorbed this impact. Net income was ¥6.4B (+39.0% YoY), reflecting the tax burden (corporate income taxes and other taxes of ¥2.7B and an effective tax rate of approximately 29.4%). The company reported higher revenue and higher earnings.

Key Financial Indicators

【Profitability】The operating margin improved to 6.1% from 3.8% in the previous year, while the net profit margin also increased to 4.0%. The gross margin was 26.2%, broadly in line with the previous year, indicating that the improvement in profitability was primarily attributable to SG&A efficiency.【Cash Flow Quality】Cash and deposits were ¥45.7B, slightly down from ¥46.5B in the previous year, while accounts receivable of ¥237.0B and inventories of ¥133.3B represented substantial asset balances.【Investment Efficiency】ROE was 1.8%, a level explained by the combination of the net profit margin, total asset turnover (approximately 0.18x), and financial leverage (approximately 2.45x).【Financial Soundness】The equity ratio was 40.9%, improving from 38.8% in the previous year. Total assets declined to ¥874.7B from ¥903.2B in the previous year, while net assets increased to ¥357.5B.

Cash Flow Analysis

As the cash flow statement was not disclosed, cash flow trends are assessed based on changes in the balance sheet. Cash and deposits were ¥45.7B, a slight decrease from ¥46.5B in the previous year. Short-term borrowings declined YoY, moving from ¥244.9B to around ¥244.9B, although interest-bearing debt remains heavily weighted toward short-term obligations. Accounts receivable declined from ¥237.0B to the ¥269.0B range, while inventories were broadly flat, moving from ¥133.3B to the ¥135.3B range; accordingly, the scope for working capital reduction is limited. While total assets contracted from ¥874.7B to ¥903.2B, net assets increased from ¥357.5B to ¥350.6B, indicating a slight improvement in capital efficiency.

Earnings Quality

There appears to have been no impact from extraordinary gains or losses on earnings for the current period, which can therefore be viewed as having arisen from recurring business activities. Non-operating income was ¥1.9B, equivalent to 1.2% of revenue, indicating a low degree of dependence, while interest expense of ¥1.0B accounted for the increase in interest burden among non-operating expenses of ¥2.5B. Operating income of ¥9.7B declined stepwise to ordinary income of ¥9.1B and net income of ¥6.4B due to non-operating gains and losses and the tax burden; this structure was not materially different from the previous year. The fact that SG&A reductions were the primary driver of earnings growth indicates that cost efficiency contributed more than a qualitative transformation in the earnings structure, and its sustainability will depend on future SG&A trends.

Earnings Forecast and Guidance

The full-year forecast is revenue of ¥632.0B (YoY +1.4%), operating income of ¥20.0B (YoY -24.2%), ordinary income of ¥14.0B (YoY -40.4%), and net income of ¥13.0B (YoY -35.4%). Q1 progress was approximately standard at 25.4% for revenue, while profit items were significantly ahead of schedule, at 48.6% for operating income, 65.1% for ordinary income, and 49.4% for net income. Given that the full-year forecast assumes lower earnings YoY, the significant earnings growth in Q1 suggests either a concentration in the first half or upside potential relative to the cautious full-year outlook.

Shareholder Returns

The full-year dividend forecast is ¥90 per share, with no revisions to the dividend forecast during the current quarter. The payout ratio against the full-year forecast EPS of ¥152.25 is approximately 59.1%. As the dividend was ¥45 in the previous year, the full-year forecast of ¥90 represents a plan to increase the annualized dividend.

Risk Factors

1. Working capital efficiency risk: Accounts receivable of ¥237.0B and inventories of ¥133.3B represent substantial asset balances, and delays in collections or inventory turnover could constrain cash generation.

2. Refinancing risk associated with reliance on short-term funding: Short-term borrowings were ¥244.9B, compared with long-term borrowings of ¥18.2B, indicating that the majority of interest-bearing debt is concentrated in short-term obligations. If interest rates rise, interest expense (¥1.0B in the current period versus ¥0.7B in the previous year) could increase further.

3. Sustainability risk of SG&A efficiency gains: Earnings growth in the current period depended heavily on the improvement in the SG&A ratio (20.1% versus 22.5% in the previous year); if cost controls are reversed, the improvement in profitability could reverse.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

The company's profitability is significantly below the industry median, placing it in the low-profitability group within the pharmaceutical industry.

Growth and Capital Efficiency

The revenue growth rate also remains below the industry median, indicating that top-line growth is relatively modest within the industry.

※Source: Compiled by the Company

Key Points in the Results

1. Earnings growth in the current period was primarily driven by a significant improvement in the SG&A ratio (-2.4pt), while the gross margin was broadly flat. This structure reflects the substantial impact of cost controls rather than an improvement in product mix, making the monitoring of SG&A trends in subsequent quarters key to assessing sustainability.

2. While the full-year forecast assumes lower earnings YoY, progress for profit items in Q1 was significantly ahead of schedule at 48–65%. This contrast suggests either conservatism in the full-year outlook or the possibility of expense normalization and convergence in profitability toward the second half.

3. Short-term borrowings account for the majority of interest-bearing debt, and interest expense increased by ¥0.3B from the previous year. Together with substantial working capital balances (accounts receivable and inventories), this indicates relatively high sensitivity to the interest-rate environment and the timing of funding requirements.

Theoretical Share Price (Reference Value)

Sensitivity: ¥3,448–¥3,643 at ±1% for the cost of equity, and ¥3,523–¥3,557 at ±0.1 for ω.

Notes:

• Because progress of net income against the full-year forecast (49%) exceeds the standard level (25%), forecast EPS has been adjusted upward within an upper limit of +10% (because companies with progress ahead of schedule tend to outperform forecasts; adjustments may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated at a somewhat high level.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional where necessary.

---End of Report---